Efficacy of GV1001 with gemcitabine/capecitabine in previously untreated patients with advanced pancreatic ductal adenocarcinoma having high serum eotaxin levels (KG4/2015): an open-label, randomised, Phase 3 trial.
Journal Information
Full Title: Br J Cancer
Abbreviation: Br J Cancer
Country: Unknown
Publisher: Unknown
Language: N/A
Publication Details
Related Papers from Same Journal
Transparency Score
5/6
83.3% Transparent
Transparency Indicators
Click on green indicators to view evidence textCore Indicators
Data Sharing
Evidence found in paper:
"data availability the raw protein microarray data generated in our study is available in the geo database under accession number gse212575. data availability the raw protein microarray data generated in our study is available in the geo database under accession number gse212575"
Code Sharing
COI Disclosure
Evidence found in paper:
"Competing interests SK is an employee of GemVax & KAEL Co., Ltd. The remaining authors declare no competing interests."
Funding Disclosure
Evidence found in paper:
"Funding The funding for this research was supported by Samsung Pharm. Ltd."
Protocol Registration
Evidence found in paper:
"Clinical trial registration NCT02854072."
Open Access
Paper is freely available to read
Additional Indicators
Replication
Novelty Statement
Assessment Info
Tool: rtransparent
OST Version: N/A
Last Updated: Aug 05, 2025